Milestones

1. Contribution to obtaining the first GlauCCare accreditation for glaucoma for an Ophthalmology service in Spain. This standard is based on quality indicators and health outcomes. This milestone reinforces the integration between clinical practice and translational research, promoting the analysis of real-world results and the development of evidence-based care models and continuous improvement.
2. Prominent participation in the first human clinical trial in Spain of a 3D-printed corneal implant to treat corneal melting, developed in collaboration with IdiPAZ. The human collagen implant acts as structural support in corneas with severe thickness loss and has demonstrated safety and efficacy in preclinical studies.
3. Renewal of participation in the RICORS Network for Inflammatory Diseases (RD24/0007/0020), funded by the ISCIII, consolidating the group's role in collaborative research in personalized medicine and strengthening the study of ocular inflammation through multicenter collaboration and a translational approach.
4. The group has consolidated its position by securing a health research project funded by the ISCIII (PI22/01252), focused on integrating multicenter registries, advanced medical imaging, and artificial intelligence applied to personalized medicine in ocular pathology. This line of research includes the development of AI tools for biomarker analysis, disease progression prediction, and improved surgical outcomes, particularly in corneal pathologies such as Fuchs' endothelial dystrophy.
5. Participation in international initiatives such as Fight Retinal Blindness / Save Sight Registries reinforces the group's standing in translational research, generating real-world evidence, and developing predictive models aimed at improving visual health outcomes.